CDKN2A and neoplasm: In a study of 24 ESFT, patients with tumours that had a mutation/deletion of p16 (4/24; 17%) had a worse event-free survival than those without (P=0.019; Tsuchiya et al, 2000), and in a second study, patients with deletions of p16 (7/39; 18%) were shown to have a worse disease-specific survival than those without (P=0.001; Wei et al, 2000).